Europe Soft Tissue Sarcoma Market By Treatment (Targeted Therapy, Chemotherapy, Anti-Angiogenesis Drug, Radiation Therapy), By Disease Type (Local Sarcoma, Regional Sarcoma, Metastatic Sarcoma), By End User (Hospitals & Clinics, Ambulatory Surgical Centers, Others), By Country, Competition, Forecast & Opportunities, 2028

  • Industry : Healthcare
  • Pages : NA
  • Published Date : NA
Customization Enquiry

Buy Now

Summary

Report Description

Europe soft tissue sarcoma market is expected to grow at a significant rate during the forecast period, 2024-2028. Rise in the incidence and prevalence of different types of cancers coupled with the increasing research & development (R&D) activities is anticipated to bolster the growth of the market. Rising number of people suffering from soft tissue sarcoma in the region is augmenting the growth of the market. The advent of advanced therapies such as targeted and biological are also a contributing factor. There is growing focus on personalized medicine along with the huge investment for anti-cancer treatment research, which is likely to discover the new paths for Europe soft tissue sarcoma treatment market in the coming future. Furthermore, there is an increase in number of clinical trials going on in the region which is facilitating the growth of the market. Rising ease in FDA approvals as well as the patent expiry of branded drugs are some of the factors fuelling the growth of the market.

Soft tissue sarcoma is a rare type of cancer that develops in soft tissues of a human body such as fat, muscle, nerves, fibrous tissues, or deep skin tissues. About 40 percent of the cases occur in the legs usually at or above the knee. Fifteen percent develop in the hands and arms, another 15 percent in the head and neck and remaining 30 percent in the shoulders, chest, abdomen, or hips. Moreover, it is not classified as tumour, but can be life-threatening if the cancer spreads in the human body.

Increasing Prevalence of Different Types of Cancers

Growing occurrences of various types of cancer which start in soft tissues such as tendons, fat, nerves, blood vessels, and others, are expected to propel the growth of the market. There is a rise in number of cases of sarcoma which is augmenting the growth of the market. According to the cancer research UK, there are about 4,300 new soft tissue sarcoma cases in England every year, which is around 12 every day. Elder population are more at risk as they can develop soft tissue sarcomas cancer. Around 40 in 100 soft tissue sarcomas (40%) are diagnosed in individual’s aged 65 or above.


Download Free Sample Report

Increasing Research & Development (R&D) Activities

There is rise in number of research activities on drugs and other therapies which is likely to bolster the growth of the market. Researchers are focusing on second-line therapies for the patients who relapse or are refractory as there is no approved therapies for the same. Heavy funding by the government as well as private sectors for the R&D purpose are facilitating the growth of the market.

Rise in Number of Clinical Trials

There are large number of clinical studies which are going on for the soft tissue sarcoma in the region, which is projected to bolster the growth of the market. There is total 578 clinical studies in Europe, out of which 242 studies are completed. For instance, in 2021, a clinical trial for the “NBTXR3 Crystalline Nanoparticles and Radiation Therapy in Treating Randomized Patients in Two Arms with Soft Tissue Sarcoma of the Extremity and Trunk Wall” was completed.

Market Segmentation

Europe soft tissue sarcoma market is segmented into treatment, disease type, end user, company, and country. Based on treatment, the market is divided into targeted therapy, chemotherapy, anti-angiogenesis drug, and radiation therapy. Based on disease type, the market is categorized into local sarcoma, regional sarcoma, and metastatic sarcoma. Based on end user, the market is bifurcated into hospitals & clinics, ambulatory surgical centers, and others. In terms of countries, the market is categorized into Germany, France, United Kingdom, Italy, Spain, Netherlands, Belgium, Sweden, Poland, and Greece.

Market Players

GlaxoSmithKline PLC, Eli Lilly Italia - S.p.A., Pfizer Deutschland GmbH., Bristol-Myers Squibb SARL, F. Hoffmann-La Roche AG, Teva Pharmaceuticals Europe BV, Celgene Europe Ltd, Zimmer GmbH, RTI UK Ltd, and Integra LifeSciences Services France SASU, are some of the leading companies in the market.

Attribute

Details

Base Year

2022

Historic Data

2018 – 2021

Estimated Year

2023

Forecast Period

2024 – 2028

Quantitative Units

Revenue in USD Million and CAGR for 2018-2022 and 2023-2028

Report coverage

Revenue forecast, company share, competitive landscape, growth factors, and trends

Segments covered

Treatment

Disease Type

End User

Country

Country scope

Germany, France, United Kingdom, Italy, Spain, Netherlands, Belgium, Sweden, Poland, and Greece

Key companies profiled

GlaxoSmithKline PLC, Eli Lilly Italia - S.p.A., Pfizer Deutschland GmbH., Bristol-Myers Squibb SARL, F. Hoffmann-La Roche AG, Teva Pharmaceuticals Europe BV, Celgene Europe Ltd, Zimmer GmbH, RTI UK Ltd and Integra LifeSciences Services France SASU.

Customization scope

10% free report customization with purchase. Addition or alteration to country, & segment scope.

Pricing and purchase options

Avail customized purchase options to meet your exact research needs. Explore purchase options

Delivery Format

PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)

Report Scope:

In this report, Europe soft tissue sarcoma market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

  • Europe Soft Tissue Sarcoma Market, By Treatment:
    • Targeted Therapy
    • Chemotherapy
    • Anti-Angiogenesis Drug
    • Radiation Therapy
  • Europe Soft Tissue Sarcoma Market, By Disease Type:
    • Local Sarcoma
    • Regional Sarcoma
    • Metastatic Sarcoma
  • Europe Soft Tissue Sarcoma Market, By End User:
    • Hospitals & Clinics
    • Ambulatory Surgical Centers
    • Others

·         Europe Soft Tissue Sarcoma Market, By Country:

    • France
    • Germany
    • United Kingdom
    • Italy
    • Spain
    • Belgium
    • Netherlands
    • Sweden
    • Poland
    • Greece

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in Europe soft tissue sarcoma market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company’s specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Profit Margin Analysis

  • Profit margin analysis in case of direct and indirect sales channel.

It is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]

Table of content

1.    Product Overview

1.1.  Market Definition

1.2.  Scope of the Market

1.2.1.     Markets Covered

1.2.2.     Years Considered for Study

1.2.3.     Key Market Segmentations

2.    Research Methodology

2.1.  Objective of the Study

2.2.  Baseline Methodology

2.3.  Key Industry Partners

2.4.  Major Association and Secondary Sources

2.5.  Forecasting Methodology

2.6.  Data Triangulation & Validation

2.7.  Assumptions and Limitations

3.    Executive Summary

3.1.  Overview of the Market

3.2.  Overview of Key Market Segmentations

3.3.  Overview of Key Market Players

3.4.  Overview of Key Regions/Countries

3.5.  Overview of Market Drivers, Challenges, Trends

4.    Voice of Customer

5.    Europe Soft Tissue Sarcoma Market Outlook

5.1.  Market Size & Forecast

5.1.1.     By Value

5.2.  Market Share & Forecast

5.2.1.     By Treatment (Targeted Therapy, Chemotherapy, Anti-Angiogenesis Drug, Radiation Therapy)

5.2.2.     By Disease Type (Local Sarcoma, Regional Sarcoma, Metastatic Sarcoma)

5.2.3.     By End User (Hospitals & Clinics, Ambulatory Surgical Centers, Others)

5.2.4.     By Country

5.2.5.     By Company (2022)

5.3.  Market Map

5.3.1.     By Treatment

5.3.2.     By Disease Type

5.3.3.     By End User

5.3.4.     By Country

5.4.  Europe: Country Analysis

5.4.1.     Germany Humanized Mice Model Market Outlook

5.4.1.1.         Market Size & Forecast

5.4.1.1.1.             By Value

5.4.1.2.         Market Share & Forecast

5.4.1.2.1.             By Treatment

5.4.1.2.2.             By Disease Type

5.4.1.2.3.             By End User

5.4.2.     France Humanized Mice Model Market Outlook

5.4.2.1.         Market Size & Forecast

5.4.2.1.1.             By Value

5.4.2.2.         Market Share & Forecast

5.4.2.2.1.             By Treatment

5.4.2.2.2.             By Disease Type

5.4.2.2.3.             By End User

5.4.3.     United Kingdom Humanized Mice Model Market Outlook

5.4.3.1.         Market Size & Forecast

5.4.3.1.1.             By Value

5.4.3.2.         Market Share & Forecast

5.4.3.2.1.             By Treatment

5.4.3.2.2.             By Disease Type

5.4.3.2.3.             By End User

5.4.4.     Italy Humanized Mice Model Market Outlook

5.4.4.1.         Market Size & Forecast

5.4.4.1.1.             By Value

5.4.4.2.         Market Share & Forecast

5.4.4.2.1.             By Treatment

5.4.4.2.2.             By Disease Type

5.4.4.2.3.             By End User

5.4.5.     Spain Humanized Mice Model Market Outlook

5.4.5.1.         Market Size & Forecast

5.4.5.1.1.             By Value

5.4.5.2.         Market Share & Forecast

5.4.5.2.1.             By Treatment

5.4.5.2.2.             By Disease Type

5.4.5.2.3.             By End User

5.4.6.     Netherlands Humanized Mice Model Market Outlook

5.4.6.1.         Market Size & Forecast

5.4.6.1.1.             By Value

5.4.6.2.         Market Share & Forecast

5.4.6.2.1.             By Treatment

5.4.6.2.2.             By Disease Type

5.4.6.2.3.             By End User

5.4.7.     Belgium Humanized Mice Model Market Outlook

5.4.7.1.         Market Size & Forecast

5.4.7.1.1.             By Value

5.4.7.2.         Market Share & Forecast

5.4.7.2.1.             By Treatment

5.4.7.2.2.             By Disease Type

5.4.7.2.3.             By End User

5.4.8.     Sweden Humanized Mice Model Market Outlook

5.4.8.1.         Market Size & Forecast

5.4.8.1.1.             By Value

5.4.8.2.         Market Share & Forecast

5.4.8.2.1.             By Treatment

5.4.8.2.2.             By Disease Type

5.4.8.2.3.             By End User

5.4.9.     Poland Humanized Mice Model Market Outlook

5.4.9.1.         Market Size & Forecast

5.4.9.1.1.             By Value

5.4.9.2.         Market Share & Forecast

5.4.9.2.1.             By Treatment

5.4.9.2.2.             By Disease Type

5.4.9.2.3.             By End User

5.4.10.  Greece Humanized Mice Model Market Outlook

5.4.10.1.      Market Size & Forecast

5.4.10.1.1.           By Value

5.4.10.2.      Market Share & Forecast

5.4.10.2.1.           By Treatment

5.4.10.2.2.           By Disease Type

5.4.10.2.3.           By End User

6.    Market Dynamics

6.1.  Drivers

6.2.  Challenges

7.    Pricing Analysis

8.    Market Trends & Developments

9.    Competitive Landscape

9.1.  Competition Outlook

9.2.  Regional Players Profiled (Leading Companies)

9.2.1.     GlaxoSmithKline PLC

9.2.2.     Eli Lilly Italia - S.P.A.

9.2.3.     Pfizer Deutschland GmbH.

9.2.4.     Bristol-Myers Squibb SARL

9.2.5.     F. Hoffmann-La Roche AG

9.2.6.     Teva Pharmaceuticals Europe BV

9.2.7.     Celgene Europe Ltd

9.2.8.     Zimmer GmbH

9.2.9.     RTI UK Ltd

9.2.10.  Integra LifeSciences Services France SASU

10.  Strategic Recommendations

Figures and Tables

Frequently asked questions

down-arrow

Growing clinical trials, rising incidences of cancer, and increasing R&D activities are driving the demand for the Europe Soft Tissue Sarcoma market.

down-arrow

GlaxoSmithKline PLC, Eli Lilly Italia - S.p.A., Pfizer Deutschland GmbH., Bristol-Myers Squibb SARL, F. Hoffmann-La Roche AG, Teva Pharmaceuticals Europe BV, Celgene Europe Ltd, Zimmer GmbH, RTI UK Ltd and Integra LifeSciences Services France SASU are the key players operating in the Europe Soft Tissue Sarcoma market.

down-arrow

Based on treatment, the market is divided into targeted therapy, chemotherapy, anti-angiogenesis drug, and radiation therapy. The chemotherapy segment is expected to dominate the growth of the market. This is because it is used alone or in combination to treat a wide variety of cancers.

down-arrow

The lack of awareness among people about this cancer as well as huge expenditure required for the treatment methods are likely to slow down the growth of Europe Soft Tissue Sarcoma market.

Related Reports

profile

Sakshi Bajaal

Business Consultant
Press Release

Europe Soft Tissue Sarcoma Market to Witness Substantial Growth through 2025

Jun, 2020

Growing pool of patients suffering from sarcoma and increasing adoption of novel therapeutics to drive the growth of Europe soft tissue sarcoma market

Why Choose Us